Skip to main content
Top
Published in: European Radiology 7/2019

Open Access 01-07-2019 | Cardiac

Acute adverse events in cardiac MR imaging with gadolinium-based contrast agents: results from the European Society of Cardiovascular Radiology (ESCR) MRCT Registry in 72,839 patients

Authors: Johannes Uhlig, Christian Lücke, Rozemarijn Vliegenthart, Christian Loewe, Matthias Grothoff, Andreas Schuster, Philipp Lurz, Alexis Jacquier, Marco Francone, Antonia Zapf, Christoph Schülke, Matthias Stefan May, Jens Bremerich, Joachim Lotz, Matthias Gutberlet, Daniel Thomas, the ESCR MRCT Registry contributors

Published in: European Radiology | Issue 7/2019

Login to get access

Abstract

Objectives

To assess the incidence of acute adverse events (AAEs) in gadolinium-enhanced cardiac magnetic resonance (CMR) imaging.

Methods

Gadolinium-based contrast agent (GBCA)–enhanced CMR data from the multinational, multicenter European Society of Cardiovascular Radiology MRCT Registry was included. AAE severity was classified according to the American College of Radiology Manual on Contrast Media (mild, moderate, severe). Multivariable generalized linear mixed effect models were used to assess the likelihood of AAEs in various GBCA, adjusting for pharmacological stressor, main indications (i.e., suspected or known coronary artery disease or myocarditis), age, sex, and submitting center as a random effect.

Results

In the study population of 72,839 GBCA-enhanced CMRs, a total of 260 AAEs were reported (0.36%), with a minority of severe AAEs (n = 24, 0.033%). Allergic-like AAEs were less likely than physiologic AAEs (29% versus 71%). Patients without pharmacological stress imaging had a lower AAE rate (0.22%) compared to stress imaging (0.75%), with the highest AAE rates for regadenoson (2.95%). AAE rates also varied by GBCA subtype (overall p < 0.001). There was significant interaction between GBCA and pharmacological stressor (interaction p = 0.025), with AAE rates ranging between 0 and 10% for certain GBCA/stressor combinations. There was further marginal evidence that higher GBCA volume was associated with higher AAE incidence (OR = 1.02, p = 0.05).

Conclusion

GBCA-enhanced CMR imaging demonstrates low AAE rates comparable to those of other body regions. AAE likelihood correlates with GBCA subtype, pharmacological stressor, and imaging indication. Intravenous fluid administration in patients with cardiac impairment might contribute to these findings.

Key Points

• Acute adverse event rates in cardiac magnetic resonance (CMR) imaging with gadolinium-based contrast agents (GBCAs) are low (0.36%), especially for severe adverse events (0.033%).
• Mild and moderate adverse events are more frequent during stress CMR imaging.
• Physiologic AAEs are more common than allergic AAEs in CMR imaging.
Appendix
Available only for authorised users
Literature
1.
go back to reference Matsumura T, Hayakawa M, Shimada F et al (2013) Safety of gadopentetate dimeglumine after 120 million administrations over 25 years of clinical use. Magn Reson Med Sci 12:297–304CrossRefPubMed Matsumura T, Hayakawa M, Shimada F et al (2013) Safety of gadopentetate dimeglumine after 120 million administrations over 25 years of clinical use. Magn Reson Med Sci 12:297–304CrossRefPubMed
2.
go back to reference Bleicher AG, Kanal E (2008) Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. AJR Am J Roentgenol 191:W307–W311CrossRefPubMed Bleicher AG, Kanal E (2008) Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. AJR Am J Roentgenol 191:W307–W311CrossRefPubMed
3.
go back to reference Prince MR, Zhang H, Zou Z, Staron RB, Brill PW (2011) Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 196:W138–W143CrossRefPubMed Prince MR, Zhang H, Zou Z, Staron RB, Brill PW (2011) Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 196:W138–W143CrossRefPubMed
4.
go back to reference Abujudeh HH, Kosaraju VK, Kaewlai R (2010) Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections. AJR Am J Roentgenol 194:430–434CrossRefPubMed Abujudeh HH, Kosaraju VK, Kaewlai R (2010) Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections. AJR Am J Roentgenol 194:430–434CrossRefPubMed
5.
go back to reference Bruder O, Schneider S, Pilz G et al (2015) 2015 update on acute adverse reactions to gadolinium based contrast agents in cardiovascular MR. large multi-national and multi-ethnical population experience with 37788 patients from the EuroCMR Registry. J Cardiovasc Magn Reson 17:58CrossRefPubMedPubMedCentral Bruder O, Schneider S, Pilz G et al (2015) 2015 update on acute adverse reactions to gadolinium based contrast agents in cardiovascular MR. large multi-national and multi-ethnical population experience with 37788 patients from the EuroCMR Registry. J Cardiovasc Magn Reson 17:58CrossRefPubMedPubMedCentral
6.
go back to reference Hunt CH, Hartman RP, Hesley GK (2009) Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR Am J Roentgenol 193:1124–1127CrossRefPubMed Hunt CH, Hartman RP, Hesley GK (2009) Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR Am J Roentgenol 193:1124–1127CrossRefPubMed
7.
go back to reference Aran S, Shaqdan KW, Abujudeh HH (2015) Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections. Clin Radiol 70:466–475CrossRefPubMed Aran S, Shaqdan KW, Abujudeh HH (2015) Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections. Clin Radiol 70:466–475CrossRefPubMed
9.
go back to reference Sinagra G, Anzini M, Pereira NL et al (2016) Myocarditis in clinical practice. Mayo Clin Proc 91:1256–1266CrossRefPubMed Sinagra G, Anzini M, Pereira NL et al (2016) Myocarditis in clinical practice. Mayo Clin Proc 91:1256–1266CrossRefPubMed
10.
go back to reference Schuster A, Morton G, Chiribiri A, Perera D, Vanoverschelde JL, Nagel E (2012) Imaging in the management of ischemic cardiomyopathy: special focus on magnetic resonance. J Am Coll Cardiol 59:359–370CrossRefPubMed Schuster A, Morton G, Chiribiri A, Perera D, Vanoverschelde JL, Nagel E (2012) Imaging in the management of ischemic cardiomyopathy: special focus on magnetic resonance. J Am Coll Cardiol 59:359–370CrossRefPubMed
11.
go back to reference Al Sayari S, Kopp S, Bremerich J (2015) Stress cardiac MR imaging: the role of stress functional assessment and perfusion imaging in the evaluation of ischemic heart disease. Radiol Clin North Am 53:355–367CrossRefPubMed Al Sayari S, Kopp S, Bremerich J (2015) Stress cardiac MR imaging: the role of stress functional assessment and perfusion imaging in the evaluation of ischemic heart disease. Radiol Clin North Am 53:355–367CrossRefPubMed
12.
go back to reference Bruder O, Schneider S, Nothnagel D et al (2009) EuroCMR (European Cardiovascular Magnetic Resonance) Registry: results of the German pilot phase. J Am Coll Cardiol 54:1457–1466CrossRefPubMed Bruder O, Schneider S, Nothnagel D et al (2009) EuroCMR (European Cardiovascular Magnetic Resonance) Registry: results of the German pilot phase. J Am Coll Cardiol 54:1457–1466CrossRefPubMed
13.
go back to reference Bruder O, Schneider S, Nothnagel D et al (2011) Acute adverse reactions to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients from the EuroCMR Registry. JACC Cardiovasc Imaging 4:1171–1176CrossRefPubMed Bruder O, Schneider S, Nothnagel D et al (2011) Acute adverse reactions to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients from the EuroCMR Registry. JACC Cardiovasc Imaging 4:1171–1176CrossRefPubMed
14.
go back to reference Idee JM, Port M, Robic C, Medina C, Sabatou M, Corot C (2009) Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging 30:1249–1258CrossRefPubMed Idee JM, Port M, Robic C, Medina C, Sabatou M, Corot C (2009) Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging 30:1249–1258CrossRefPubMed
16.
go back to reference R Development Core Team (2008) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna R Development Core Team (2008) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
17.
go back to reference RStudio Team (2015) RStudio: integrated development for R, Boston, MA, USA RStudio Team (2015) RStudio: integrated development for R, Boston, MA, USA
18.
go back to reference Li A, Wong CS, Wong MK, Lee CM, Au Yeung MC (2006) Acute adverse reactions to magnetic resonance contrast media—gadolinium chelates. Br J Radiol 79:368–371CrossRefPubMed Li A, Wong CS, Wong MK, Lee CM, Au Yeung MC (2006) Acute adverse reactions to magnetic resonance contrast media—gadolinium chelates. Br J Radiol 79:368–371CrossRefPubMed
19.
go back to reference Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC (2007) Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults. AJR Am J Roentgenol 189:1533–1538CrossRefPubMed Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC (2007) Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults. AJR Am J Roentgenol 189:1533–1538CrossRefPubMed
20.
go back to reference Niendorf HP, Alhassan A, Geens VR, Clauss W (1994) Safety review of gadopentetate dimeglumine. Extended clinical experience after more than five million applications. Invest Radiol 29(Suppl 2):S179–S182CrossRefPubMed Niendorf HP, Alhassan A, Geens VR, Clauss W (1994) Safety review of gadopentetate dimeglumine. Extended clinical experience after more than five million applications. Invest Radiol 29(Suppl 2):S179–S182CrossRefPubMed
21.
go back to reference Nelson KL, Gifford LM, Lauber-Huber C, Gross CA, Lasser TA (1995) Clinical safety of gadopentetate dimeglumine. Radiology 196:439–443CrossRefPubMed Nelson KL, Gifford LM, Lauber-Huber C, Gross CA, Lasser TA (1995) Clinical safety of gadopentetate dimeglumine. Radiology 196:439–443CrossRefPubMed
22.
go back to reference Bruder O, Wagner A, Lombardi M et al (2013) European Cardiovascular Magnetic Resonance (EuroCMR) Registry—multi national results from 57 centers in 15 countries. J Cardiovasc Magn Reson 15:9CrossRefPubMedPubMedCentral Bruder O, Wagner A, Lombardi M et al (2013) European Cardiovascular Magnetic Resonance (EuroCMR) Registry—multi national results from 57 centers in 15 countries. J Cardiovasc Magn Reson 15:9CrossRefPubMedPubMedCentral
23.
go back to reference Ananthasubramaniam K, Weiss R, McNutt B, Klauke B, Feaheny K, Bukofzer S (2012) A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. J Nucl Cardiol 19:319–329CrossRefPubMedPubMedCentral Ananthasubramaniam K, Weiss R, McNutt B, Klauke B, Feaheny K, Bukofzer S (2012) A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. J Nucl Cardiol 19:319–329CrossRefPubMedPubMedCentral
24.
go back to reference Pape M, Zacho HD, Aaroe J, Eggert Jensen S, Petersen LJ (2016) Safety and tolerability of regadenoson for myocardial perfusion imaging—first Danish experience. Scand Cardiovasc J 50:180–186CrossRefPubMed Pape M, Zacho HD, Aaroe J, Eggert Jensen S, Petersen LJ (2016) Safety and tolerability of regadenoson for myocardial perfusion imaging—first Danish experience. Scand Cardiovasc J 50:180–186CrossRefPubMed
25.
go back to reference Brink HL, Dickerson JA, Stephens JA, Pickworth KK (2015) Comparison of the safety of adenosine and regadenoson in patients undergoing outpatient cardiac stress testing. Pharmacotherapy 35:1117–1123CrossRefPubMed Brink HL, Dickerson JA, Stephens JA, Pickworth KK (2015) Comparison of the safety of adenosine and regadenoson in patients undergoing outpatient cardiac stress testing. Pharmacotherapy 35:1117–1123CrossRefPubMed
26.
go back to reference Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE (2012) A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 19:681–692CrossRefPubMedPubMedCentral Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE (2012) A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 19:681–692CrossRefPubMedPubMedCentral
28.
go back to reference Behzadi AH, Zhao Y, Farooq Z, Prince MR (2018) Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis. Radiology 286:731CrossRefPubMed Behzadi AH, Zhao Y, Farooq Z, Prince MR (2018) Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis. Radiology 286:731CrossRefPubMed
29.
go back to reference Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. L. Erlbaum Associates, Hillsdale Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. L. Erlbaum Associates, Hillsdale
30.
go back to reference King G, Zeng L (2001) Logistic regression in rare events data. Polit Anal 9:137–163CrossRef King G, Zeng L (2001) Logistic regression in rare events data. Polit Anal 9:137–163CrossRef
32.
go back to reference Marckmann P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362CrossRefPubMed Marckmann P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362CrossRefPubMed
Metadata
Title
Acute adverse events in cardiac MR imaging with gadolinium-based contrast agents: results from the European Society of Cardiovascular Radiology (ESCR) MRCT Registry in 72,839 patients
Authors
Johannes Uhlig
Christian Lücke
Rozemarijn Vliegenthart
Christian Loewe
Matthias Grothoff
Andreas Schuster
Philipp Lurz
Alexis Jacquier
Marco Francone
Antonia Zapf
Christoph Schülke
Matthias Stefan May
Jens Bremerich
Joachim Lotz
Matthias Gutberlet
Daniel Thomas
the ESCR MRCT Registry contributors
Publication date
01-07-2019
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 7/2019
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-019-06171-2

Other articles of this Issue 7/2019

European Radiology 7/2019 Go to the issue